The short version of peptide analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-05. Anything still debated is marked as such rather than presented as settled.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
=== United Kingdom === In November 2023, Juniper was among several UK-registered online providers continuing to prescribe Ozempic for weight loss during a national shortage of semaglutide. The Advertising Standards Authority (ASA) issued an advice notice to Juniper over advertisements implying endorsement by National Health Service (NHS) workers. There were concerns about misleading claims and the promotion of prescription-onlu medicines. The ASA launched multiple investigations into online advertising by weight-loss providers, including Juniper. In June 2025, Juniper was among providers examined after test purchases showed weight-loss injections could be obtained following online questionnaires without real-time consultation. In September 2025, the growing private market for GLP-1 weight-loss medications in the UK had raised concerns about a two-tier system of access, with most users paying privately due to limited NHS availability. Juniper was offering private access to weight-loss treatments, while clinicians and public-health experts warned that cost barriers could exacerbate health inequalities and limit access for lower-income patients.
== Uses == Industry, agriculture, and other sectors employ many poisonous substances, usually for reasons other than their toxicity to humans. Examples include medicines (e.g. anthelmintics used on chickens), solvents (e.g. rubbing alcohol, turpentine), cleaners (e.g. bleach, ammonia), coatings (e.g. arsenic wallpaper), and feedstocks. The toxicity itself sometimes has economic value, when it serves agricultural purposes such as weed control and pest control. Most poisonous industrial compounds have associated material safety data sheets and are classified as hazardous substances. Hazardous substances are subject to extensive regulation on production, procurement, and use in overlapping domains of occupational safety and health, public health, drinking water quality standards, air pollution, and environmental protection. Due to the mechanics of molecular diffusion, many poisonous compounds rapidly diffuse into biological tissues, air, water, or soil on a molecular scale. By the principle of entropy, chemical contamination is typically costly or infeasible to reverse, unless specific chelating agents or micro-filtration processes are available. Chelating agents are often broader in scope than the acute target, and therefore their ingestion necessitates careful medical or veterinarian supervision. Pesticides are one group of substances whose prime purpose is their toxicity to various insects and other animals deemed to be pests (e.g., rats and cockroaches). Natural pesticides have been used for this purpose for thousands of years (e.g.
Gorky Park (officially the Central Park of Culture and Rest), named after writer Maxim Gorky, was founded in 1928. The main area (689,000 square meters or 170 acres) along the Moskva River contains estrades (raised platforms), children's attractions—including the Observation Wheel, as well as ponds with boats and water bicycles—dancing, tennis courts, and other sports facilities. Gorky Park borders the Neskuchny Garden (408,000 square meters or 101 acres), the oldest park in Moscow and a former imperial residence, created as a result of integrating three estates during the 18th century. The garden features the Green Theater, one of the largest open amphitheaters in Europe, able to contain up to 15 thousand people. Several parks include a section known as a "Park of Culture and Rest", sometimes alongside a wilder area. (Such parks include Izmaylovsky, Fili, and Sokolniki.) Some parks are designated Forest Parks (lesopark).
Despite its apparent importance in hydrogen peroxide removal, humans with genetic deficiency of catalase — "acatalasemia" — or mice genetically engineered to lack catalase completely, experience few ill effects.
==== MeSH E05.196.712 – photometry ==== MeSH E05.196.712.224 – densitometry MeSH E05.196.712.224.187 – absorptiometry, photon MeSH E05.196.712.224.375 – densitometry, x-ray MeSH E05.196.712.516 – luminescent measurements MeSH E05.196.712.516.200 – chemiluminescent measurements MeSH E05.196.712.516.600 – fluorometry MeSH E05.196.712.516.600.240 – cytophotometry MeSH E05.196.712.516.600.240.350 – flow cytometry MeSH E05.196.712.516.600.240.400 – image cytometry MeSH E05.196.712.516.600.240.400.500 – laser scanning cytometry MeSH E05.196.712.516.600.390 – fluorescence polarization MeSH E05.196.712.516.600.390.350 – fluorescence polarization immunoassay MeSH E05.196.712.516.600.393 – fluorescence recovery after photobleaching MeSH E05.196.712.516.600.410 – fluorophotometry MeSH E05.196.712.516.600.676 – spectrometry, fluorescence MeSH E05.196.712.516.600.676.500 – fluorescence resonance energy transfer MeSH E05.196.712.650 – nephelometry and turbidimetry MeSH E05.196.712.726 – spectrophotometry MeSH E05.196.712.726.300 – microspectrophotometry MeSH E05.196.712.726.551 – spectrophotometry, atomic MeSH E05.196.712.726.676 – spectrophotometry, infrared MeSH E05.196.712.726.676.700 – spectroscopy, fourier transform infrared MeSH E05.196.712.726.802 – spectrophotometry, ultraviolet
Sources: en.wikipedia.org
In hepatocellular carcinoma models, O-GlcNAc is associated with activating phosphorylation of HDAC1, which in turn regulates expression of the cell cycle regulator p21Waf1/Cip1 and cell motility regulator E-cadherin. OGT has been found to stabilize SREBP-1 and activate lipogenesis in breast cancer cell lines. This stabilization was dependent on the proteasome and AMPK. OGT knockdown resulted in decreased nuclear SREBP-1, but proteasomal inhibition with MG132 blocked this effect. OGT knockdown also increased the interaction between SREBP-1 and the E3 ubiquitin ligase FBW7. AMPK is activated by T172 phosphorylation upon OGT knockdown, and AMPK phosphorylates SREBP-1 S372 to inhibit its cleavage and maturation. OGT knockdown had a diminished effect on SREBP-1 levels in AMPK-null cell lines. In a mouse model, OGT knockdown inhibited tumor growth but SREBP-1 overexpression partly rescued this effect. These results contrast from those of a previous study which found that OGT knockdown/inhibition inhibited AMPK T172 phosphorylation and increased lipogenesis. In breast and prostate cancer cell lines, high levels of OGT and O-GlcNAc have been associated both in vitro and in vivo with processes associated with disease progression, e.g., angiogenesis, invasion, and metastasis. OGT knockdown or inhibition was found to downregulate the transcription factor FoxM1 and upregulate the cell-cycle inhibitor p27Kip1 (which is regulated by FoxM1-dependent expression of the E3 ubiquitin ligase component Skp2), causing G1 cell cycle arrest.
== History == MMPs were described initially by Jerome Gross and Charles Lapiere in 1962, who observed enzymatic activity (collagen triple helix degradation) during tadpole tail metamorphosis (by placing a tadpole tail in a collagen matrix plate). Therefore, the enzyme was named interstitial collagenase (MMP-1). Later, it was purified from human skin (1968), and was recognized to be synthesized as a zymogen. The "cysteine switch" was described in 1990.
She co-presented the 2017 BRIT Awards in February alongside Dermot O'Leary. She hosted The BRITs Are Coming for a second year in January 2018. Agreed in August 2017, she presented Your Song in October 2017, a one-off special for ITV. On 3 March 2018, Willis made a surprise appearance on Ant & Dec's Saturday Night Takeaway, as she presented Win the Ads while the main hosts playing the game as part of the show's 100th episode.
== Production == Like many aspects of nuclear power, fast breeder reactors have been subject to much controversy over the years. In 2010 the International Panel on Fissile Materials said "After six decades and the expenditure of the equivalent of tens of billions of dollars, the promise of breeder reactors remains largely unfulfilled and efforts to commercialize them have been steadily cut back in most countries". In Germany, the United Kingdom, and the United States, breeder reactor development programs have been abandoned. The rationale for pursuing breeder reactors—sometimes explicit and sometimes implicit—was based on the following key assumptions:
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.